Merck & Company (MRK) 59.88 $MRK
Global Veterinary Paraciticides Market 2014-2019: Segmented By Disease Causing Organisms, Products & Animal Types
M2 - 1 min ago
Research and Markets (http://www.researchandmarkets.com/research/flbfl5/global_veterinary) has announced the addition of the "Global Veterinary Paraciticides Market Segmented By Disease Causing Organisms, By Products, By Animal Types & By Geography - Trends & Forecasts 2014- 2019" report to their offering. The global market for paraciticides in veterinary healthcare is estimated to be worth $2.89 billion in 2014. Expected to grow at a CAGR of 6.0%, the market is set to reach US$ 3.97 billion by 2019. Veterinary pharmaceuticals, including parasiticides, have transformed the health of companion and livestock animals across the globe over the past two decades. Today, the spectrum of parasiticides for veterinary applications continues to expand with a variety of ectoparasiticides, endoparasiticides, and endectocides being launched every year. Constant innovationis leading to the emergence of novel parasiticide delivery systems as well. However, stringent regulations and norms are the major constraints for market growth, with some countries not allowing the use of paraciticides on food-producing animals. This report provides an extensive coverage of the market: By disease-causing organisms - Ectoparaciticides (Fleas, Lice, Mice) and Endoparaciticides (Gastrointestinal, nematode, heartworms,Lungworms); By species within companion and farm animals;By geography - North America, Asia-Pacific, Europe and the rest of world. A majority of the growth in the market is expected to be from the emerging markets in the Asia-Pacific and Latin American regions. Key Topics Covered: 1. Intoduction 2. Market Analysis 3. Market Dynamics 4.Global veterinary paraciticides market Segmentation 5. Competitive landscape 6. Company profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/fl...veterinary
Global Veterinary Medicinal Market Report 2014-2019 - Key Analysis of the $2 Billion Industry
M2 - 6 mins ago
Research and Markets (http://www.researchandmarkets.com/research/cn2b2h/global_veterinary) has announced the addition of the "Global Veterinary Medicinal Feed Additives Market Segmented By Products, By Livestock & By Geography - Trends & Forecasts 2014-2019" report to their offering. The Global Veterinary Medicinal feed additives market is estimated at $1.59 billion in 2014. Increasing consumption of meat and dairy products across the globe is expected to propel the market at a CAGR of 4.6 % to reach $2.02 billion by 2019 Epidemics such as bird flu, other diseases such as foot-and mouth-disease, and environmental concerns have led to increased concern over animal health around the globe, due to which, meat producers have increased their focus on feed quality and certification. Typical feed additives include vitamins, trace elements, preservatives, anti-oxidants, etc. Increasing Zoonotic and water borne diseases in animals are a triggering factor for growth in this market. North America and Asia-Pacific are the top two consumers of feed additives in the world, together accounting for more than 60% of the consumption. Asia-Pacific is estimated to be the fastest growing region for medicinal feed additives in terms of revenue. Growth is particularly high in emerging countries such as China, India, and Brazil, because of increasing income levels and rising per capita meat consumption. The restraints of the market are, increasing raw material cost and regulatory structure. This report provides an exhaustive coverage of the market through different categorizations. By type of product - Antibiotics, Vitamins, Antioxidants, Amino Acids, Feed Enzymes, Acidifiers, Prebiotics & Probiotics, Minerals, and Others; By live stock - Swine, Poultry, Cattle, Aquaculture and others Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Global Veterinary Medicinal Feed Additives Market Segmentation 6. Company Profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/cn...veterinary
Companion Animal Health Market 2014-2019 - Opportunities & Forecasts for the $13 Billion Industry
M2 - 19 mins ago
Research and Markets (http://www.researchandmarkets.com/research/wdsnh6/_companion_animal) has announced the addition of the " Companion Animal Health Market By Products, By Diagnostic Technologies, By Animals Type, By Geography-Trends And Forecast (2014-2019)" report to their offering. The global market for companion animal healthcare is valued at $8.5 billion in 2013. Expected to grow at a CAGR of 7.86%, the market is set to reach $13.37 billion by 2019 The companion animal health market is segmented based on type of products i. e Vaccines, Paraciticides, Anti-infectives, Medicinal feed additives, and other pharmaceuticals, based on diagnostics i.e Enzyme Linked Immuno sorbent assay(ELISA), Rapid Immuno Migration( RIM), based on genetics,based on geography market is divided into North America, Asia-Pacific, Europe and Rest of World. Europe accounts for the largest share of the animal vaccines market, followed by North America. The developing regions like Asia-pacific and Africa are expected to form a new revenue pocket in the market. Countries such as India, China, Brazil will be the major contributors in the market. Scope of the Report Products - Vaccines - Paraciticides - Anti-Infectives - Medicinal Feed Additive - Other Pharmaceuticals Diagnostic Technologies Animals Type - Dogs - Cats - Horses Key Topics Covered: 1.Introduction 2. Market Analysis 3. Market Dynamics 4.Market Segmentation 5. Global Companion Animal Diagnostics Market 6. Global Companion Animal Genetics Market 7. Global Companion Market Segmentation, By Geography 8. Competitive landscape 9. Company Profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/wd...ion_animal
Global Veterinary Vaccines Market 2014-2019 - Key Analysis of the $12 Billion Industry
M2 - 56 mins ago
Research and Markets (http://www.researchandmarkets.com/research/rrcznt/global_veterinary) has announced the addition of the "Global Veterinary Vaccines Market Segmented By Veterinary Diseases , By Technology, By Animal Type & By Geography - Trends And Forecast 2014-2019" report to their offering. The global market for veterinary vaccines is estimated to be worth $12.0 billion in 2014 and is expected to grow at a CAGR of 8.8 %, the market is set to reach a value of US$19 billion by 2019 The global veterinary vaccine market is segmented based on type of disease in companion and farm animals - poultry vaccines (Bronchitis, Avian Influenza, Marek's disease, New castle disease), Swine vaccines (Porcine reproductive disease, Swine influenza, Swine Pneumonia). Based on vaccine technology, the market is segmented into toxoid vaccines, recombinant vaccines, Inactivated vaccines and Live attenuated vaccines. Based on geography, the market is divided into North America, Asia-Pacific, Europe and the rest of world. Europe accounts for the largest share of the animal vaccines market, followed by North America. Developing regions like Asia-pacific and Africa are expected to form a new revenue pocket in the market. Countries such as India, China, Brazil will be the major contributors to the market. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Global veterinary vaccine market Segmentation, By Type of Animals,based on diseases 5. Competitive landscape 6. Company profiles 7. Appendix Companies Featured: - Zoetis Animal Healthcare - Merck - Merial (Animal Health Division Of Sanofi) - Elanco - Bayer Healthcare - Novartis Animal Health, Inc. - Virbac - Boehringer Ingelheim For more information visit http://www.researchandmarkets.com/research/rr...veterinary
Asia-Pacific Veterinary Healthcare Market 2014-2020 - Products, Veterinary Diagnostic Technologies, Veterinary Genetics & By Animal Types
M2 - 1 hr 1 min ago
Research and Markets (http://www.researchandmarkets.com/research/qlpr25/asiapacific) has announced the addition of the "Asia-Pacific Veterinary Healthcare Market Segmented By Products, Veterinary Diagnostic Technologies, Veterinary Genetics, By Animal Types - Trends & Forecasts 2014-2019" report to their offering. The Veterinary healthcare market in the Asia-Pacific region is estimated to increase at a CAGR of 8.97% to reach $2.52 billion by 2019 Better standards of living have resulted in an increase in pet ownership and livestock product consumption across the Asia Pacific region. With more pet owners willing to pay for veterinary care, the demand for supplements and other treatment options for companion animals is on the rise. Increasing consumer concern for where and how their food is produced is leading to a tougher scrutiny of feeding and rearing practices of farm animals. All the same, increased competition for cultivated land and scarcity of arable land could affect the animal healthcare market in terms of demand from livestock production. This report provides an exhaustive coverage of the market with multi-level segmentation focusing on animal species (farm animals and companion animals), type of healthcare products (vaccines, paraciticides, anti-infectives, medicinal feed additives, and other pharmaceuticals) and by geography. Regional coverage includes a study of the animal healthcare markets in India, China, Japan. Demand for Veterinary healthcare products and services in Japan is currently the largest of all countries in Asia-Pacific. However, Japan is slated to lose its leader status due heavy regulation requiringrigorous testing - much of it unnecessary. The market for Veterinary pharmaceuticals and biological products in Asia-Pacific has seen scant growth for many years, generally around 1.5%, while global growth has generally been in the 3-4% range. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Animal Types, Based On Products 5. Asia-Pacific Veterinary Diagnostics Market 6. Asia-Pacific Veterinary Genetics Market 7.Animal Species 8. Country Level Analysis 9. Competitive Landscape 10. Company Profiles - Bayer Healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis Animal Healthcare For more information visit http://www.researchandmarkets.com/research/ql...siapacific
Global Veterinary Healthcare Market - Growth, Trends And Forecasts (2014 - 2019)
M2 - 1 hr 1 min ago
Research and Markets (http://www.researchandmarkets.com/research/6g9dn6/global_veterinary) has announced the addition of the "Global Veterinary Healthcare Market - Growth, Trends And Forecasts (2014 - 2019)" report to their offering. The global veterinary health market is valued at $24.80 billion in 2014. Expected to grow at a CAGR of 7.86% to 2019, the demand for animal healthcare products and services globally is set to reach $34.39 billion by 2019 The market is segmented based on type of species (Farm Animals, Companion Animals) and by type of products (Vaccines, Paraciticides, Anti-infectives, Medicinal Feed Additives, and other pharmaceuticals). Based on geography, the market is divided into North America, Asia-Pacific, Europe and the rest of world. Europe accounts for the largest share of the animal vaccines market, followed by North America. Developing regions in Asia-pacific and Africa are expected to form a new revenue pocket in the market. Countries such as India, China, Brazil will be the major contributors to the market. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Market Segmentation- Global Animal Healthcare 5. Competitive landscape 6. Top Players in the Market 7. Appendix Companies Mentioned - Bayer Animal Health - Boehringer Ingelheim - Elanco Animal Health - Merck Ltd. - Merial ( Animal Health division of Sanofi) - Novartis Animal Health - Virbac Animal Health - Zoetis Animal Healthcare For more information visit http://www.researchandmarkets.com/research/6g...veterinary
Global Veterinary Anti-Infectives Market 2014-2020: Segmented By Veterinary Disease Types, By Animal Types & By Geography
M2 - 1 hr 2 mins ago
Research and Markets (http://www.researchandmarkets.com/research/m7q5jd/global_veterinary) has announced the addition of the "Global Veterinary Anti-Infectives Market Segmented By Veterinary Disease Types, By Animal Types & By Geography - Trends & Forecasts 2014-2019" report to their offering. Global market for veterinary anti-infectives is estimated to be worth $4.37 billion in 2014. Expected to grow at a healthy CAGR of 8.5%, the market is set to reach $6.92 billion by 2019 For the past several decades, the veterinary health business units have been able to take advantage of antibiotics that have been sidelined by parent companies and to commercialize, for food animal applications, those products that were considered unsuitable for development as human medicine- owing to market share considerations. The veterinary anti-infectives market is growing at a steady pace to combat the increasing number of infectious diseases in animals.Major constraint for the market is the high raw material cost, which makes anti-infective drugs not easily accessible to a majority of the animal population. However, with continuous innovation and rapid technological advancement, the chances of reducing the cost of anti-infective drugs are high. This report provides an exhaustive coverage of the veterinary anti-infectives market through different categorizations. By type of products - Marbofloaxcine, Florfenicol, Freeze-dried ceftiofur, Beta-lactams, Oxytetracycline and Amminosidin; By species within companion farm animals; By Geography -North America, Asia-Pacific, Europe and Rest of World. Key Topics Covered: 1. Introduction 2.Market Analysis 3.Market Dynamics 4.Global Veterinary Anti-Infective Market Segmentation 5. Competitive landscape 6. Company profiles 7. Appendix Companies Mentioned - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/m7...veterinary
North America Veterinary Healthcare Market - Products, Diagnostic Technologies, Genetics, By Animal Types 2014-2019
M2 - 1 hr 6 mins ago
Research and Markets (http://www.researchandmarkets.com/research/qn5x36/north_america) has announced the addition of the "North America Veterinary Healthcare Market Segmented By Products, Diagnostic Technologies, Genetics, By Animal Types & Geography- Trends & Forecasts-2014-2019" report to their offering. The market for veterinary healthcare products and services in North America is slated to grow at a healthy CAGR to reach $8.6 billion by 2019 from $6.2 billion in 2014 With more pet owners willing to pay for veterinary care, the demand for supplements and other treatment options for companion animals is on the rise. Increasing consumer concern for where and how their food is produced is leading to a tougher scrutiny of feeding and rearing practices of farm animals. All the same, increased competition for cultivated land and scarcity of arable land could affect the animal healthcare market in terms of demand from livestock production. Veterinary healthcare has shifted from providing producers with a set of tools for better livestock productivity to providing safer food sources for the end consumers. Such a shift in priorities, as a result of demand pressures, has played a key role in the rise of demand for this market. Increasing cases of zoonotic and foodborne diseases have prompted tougher regulations and testing procedures, especially in North America, prompting innovation in animal healthcare. This report provides an exhaustive coverage of the market with multi-level segmentation focusing on animal species (farm animals and companion animals), type of healthcare products (vaccines, paraciticides, anti-infectives, medicinal feed additives, and other pharmaceuticals) and by geography. Regional coverage includes a study of the animal healthcare markets in the US, Canada and Mexico. The United States is the largestmarket in this region, owing to ownership trends favoring higher spending on preventative pet healthcareproducts such as parasiticides and supplements with nutritional chemical content. Pfizer, Merck, Sanofi-Aventis, Bayer HealthCare, Virbac, Novartis, Boehringer Ingelheim, Heska Corporation, Bioniche Animal Health Canada, Inc., and Ceva are the key players in the North American animal health care market. Key Topics Covered: 1. Introduction 2 Market Analysis 3. Market Dynamics 4. North America Veterinary healthcare Market Segmentation- Animal Types, based on products 5. North America Veterinary Diagnostics Market 6.North America Veterinary Genetics Market 7. North America Veterinary Healthcare Market Segmentation- By Animal Species 8. North America Veterinary healthcare market- Country level Analysis 9. Competitive landscape 10. Company profiles 11. Appendix Companies Mentioned - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/qn...th_america
Canada Veterinary Healthcare Market 2014-2019: Animal Types (Farm Animals, Companion Animals, Poultry) & Diagnostics Technologies
M2 - 1 hr 6 mins ago
Research and Markets (http://www.researchandmarkets.com/research/5b25bm/canada_veterinary) has announced the addition of the "Canada Veterinary Healthcare Market- By Animal Types (Farm Animals, Companion Animals, Poultry), By Diagnostics Technologies -Trends And Forecast, 2014 - 2019" report to their offering. The market for vaccines in 2014 is estimated to be US$484 million and is expected to grow at a CAGR of 5.36% between 2011 and 2019, to reach US$628 million by 2019 The market for paraciticides in the region is currently at US$ 113 million - a significant increase from 2013. Increasing focus on food safety and animal health will drive the market for medicinal feed additives to grow at a healthy CAGR of 7%. This report is a study of Canada's veterinary healthcare market, recent trends, current market estimates and forecasts. Veterinary healthcare in Canada has had a significant boost in revenues due to a number of factors. Prominent among them are the escalating occurrence of zoonotic diseases, growing consumer focus on animal health and food safety, and increasing pet ownership. Going forward, the key factor for the growth of Canada's animal health market will be the need to increase production of farm animal products (eggs, milk, beef and other dairy products). Key companies operating in the animal healthcare market in Canada are Zoetis, Merck, Merial, Bayer and Novartis. Growth strategies adopted by these players in the past have differed significantly. While a few like Zoestis and Bayer animal healthcare have focused on horizontal growth by expanding their presence in emerging markets, others like Elanco and Novartis animal healthcare have been content to operate within their established boundaries, going in for vertical growth by product innovation instead. Key Topics Covered: 1. Introduction 2. Key Findings Of The Study 3 Canada Veterinary Healthcare Market - Overview 4. Global Market Analysis 5.Canada's Share In The North America Veterinary Health Care Market. 6. Canada's Veterinary Health Care Market- Market Segmentation By Products 7. Canada's Veterinary Health Care Market- Market Segmentation By Animals 8. The Future Of The Industry-Expert View 9. Key Players' Profile - Global - Bayer Animal Health - Elanco Animal Health - Merck Ltd. - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health - Zoetis Animal Healthcare For more information visit http://www.researchandmarkets.com/research/5b...veterinary
Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 6:15PM CDT
Merck & Co. Inc. (MRK) announced encouraging data from a pivotal phase III fracture outcomes study evaluating the use of odanacatib in postmenopausal women suffering from osteoporosis.
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab
Business Wire - Wed Sep 17, 12:38PM CDT
Merck & Co., Inc. known as MSD outside the United States and Canada, and Sun Pharma through their respective subsidiaries, today announced an exclusive worldwide licensing agreement for Merck's investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment.
Human Microbiome Market - Disease, Application & Products Breakdown - Global Forecast to 2023
M2 - Wed Sep 17, 10:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l4973v/human_microbiome) has announced the addition of the "Human Microbiome Market by Disease, Application & by Product - Global Forecast to 2023" report to their offering. For the purposes of this report, the human microbiome market is segmented by application, disease, product, and geography. The human microbiome market is expected to be valued as $294 million in 2019 and is poised to grow at a CAGR of 22.3% within the forecast period of 2019-2023. The market is driven by growing incidences of unhealthy lifestyle diseases, and increase in occurrence of autoimmune disorders. However, government regulation and lack of detailed research may restrain the growth of this market to an extent. Investing in probiotic and prebiotic products, medical foods, drugs, and devices will prove fruitful for companies in the future. The applications segment is further subdivided into therapeutics and diagnostics. Therapeutics may be the leading segment, owing to growing population and diseases. Currently, the diagnostics segment has fewer products in the pipeline than the therapeutics segment. The disease market is subdivided into the obesity, diabetes, autoimmune disorders, cancer, acute diarrhea, mental disorders and others segments. Of these, obesity and acute diarrhea are expected to be the leading segments; acute diarrhea is expected to show the fastest growth . This growth will driven by the rise in lifestyle diseases, aging population and high adoption rates of approved products. The products segment is subdivided into probiotics, prebiotics, foods, medical foods, other supplements, devices, and drugs. Growth in these segments will be majorly driven due to use of probiotics and prebiotics for maintaining gut flora to avoid lifestyle diseases. The key players in the human microbiome market are Enterome Bioscience (France), Yakult Honsha Co., Ltd. (Japan), E. I. Du Pont de Nemours and company (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome, Inc. ( U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences, Inc. (U.S.), Osel, Inc. (U.S.), and Merck & Co, Inc. (U.S.) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Human Microbiome Market, By Disease 8 Human Microbiome Market, By Application 9 Market, By Product 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles - E. I. Du Pont De Nemours And Company - Enterome Bioscience - Merck & Co., Inc. - Metabiomics Corporation - Microbiome Therapeutics Llc. - Osel Inc. - Second Genome, Inc. - Vedanta Biosciences - Vithera Pharmaceuticals - Yakult Honsha Co., Ltd. For more information visit http://www.researchandmarkets.com/research/l4...microbiome
Sun Pharma licenses Merck psoriasis drug for $80M
AP - Wed Sep 17, 10:10AM CDT
NEW YORK (AP) — Merck is licensing an experimental psoriasis drug to Indian drugmaker Sun Pharmaceuticals, the companies said Wednesday.
Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
Business Wire - Wed Sep 17, 8:31AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Merck's investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to Merck's once-daily DPP-4 inhibitor JANUVIA(R) (sitagliptin) 50 mg, which is the standard starting dose for sitagliptin in Japan. Merck presented these data on omarigliptin, which has been shown to produce sustained DPP-4 inhibition, at an oral session at the 50th European Association for the Study of Diabetes (EASD) Annual Meeting.
Global Hepatitis C Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead, Johnson & Johnson, Merck and Vertex Pharmaceuticals
PR Newswire Europe - Wed Sep 17, 6:26AM CDT
DUBLIN, Sept. 17, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/n8ttk9/global_hepatitis] has announced the addition of the "Global Hepatitis C Market 2014-2018" [http://www.researchandmarkets.com/research/n8ttk9/global_hepatitis] report to their offering.
OncoSec Medical Expands Legal Team, Appoints Sheela Mohan-Peterson as General Counsel and Corporate Secretary
Business Wire - Wed Sep 17, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has appointed Sheela Mohan-Peterson, J.D., M.S. to the position of General Counsel and Corporate Secretary. In this newly created role, she will be responsible for leading the Company's global legal strategy and guiding the continued expansion of its intellectual property portfolio. Ms. Mohan-Peterson will be supported by an experienced internal legal team that includes legal associate and paralegal positions.
Dow Jones (DJIA) Today: Merck (MRK) Higher
at The Street - Tue Sep 16, 1:00PM CDT
The Dow component leading the way higher looks to be Merck (NYSE:MRK), which is sporting a 34-cent gain (+0.6%) bringing the stock to $59.86.
Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis
PR Newswire Europe - Tue Sep 16, 12:53PM CDT
DUBLIN, Sept. 16, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/jq2qvt/global_animal] has announced the addition of the "Global Animal Vaccines Market 2014-2018" [http://www.researchandmarkets.com/research/jq2qvt/global_animal] report to their offering.
Global Veterinary Paraciticides Market 2014-2019: Segmented By Disease Causing Organisms, Products & Animal Types
M2 - 1 min ago
Research and Markets (http://www.researchandmarkets.com/research/flbfl5/global_veterinary) has announced the addition of the "Global Veterinary Paraciticides Market Segmented By Disease Causing Organisms, By Products, By Animal Types & By Geography - Trends & Forecasts 2014- 2019" report to their offering. The global market for paraciticides in veterinary healthcare is estimated to be worth $2.89 billion in 2014. Expected to grow at a CAGR of 6.0%, the market is set to reach US$ 3.97 billion by 2019. Veterinary pharmaceuticals, including parasiticides, have transformed the health of companion and livestock animals across the globe over the past two decades. Today, the spectrum of parasiticides for veterinary applications continues to expand with a variety of ectoparasiticides, endoparasiticides, and endectocides being launched every year. Constant innovationis leading to the emergence of novel parasiticide delivery systems as well. However, stringent regulations and norms are the major constraints for market growth, with some countries not allowing the use of paraciticides on food-producing animals. This report provides an extensive coverage of the market: By disease-causing organisms - Ectoparaciticides (Fleas, Lice, Mice) and Endoparaciticides (Gastrointestinal, nematode, heartworms,Lungworms); By species within companion and farm animals;By geography - North America, Asia-Pacific, Europe and the rest of world. A majority of the growth in the market is expected to be from the emerging markets in the Asia-Pacific and Latin American regions. Key Topics Covered: 1. Intoduction 2. Market Analysis 3. Market Dynamics 4.Global veterinary paraciticides market Segmentation 5. Competitive landscape 6. Company profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/fl...veterinary
Global Veterinary Medicinal Market Report 2014-2019 - Key Analysis of the $2 Billion Industry
M2 - 6 mins ago
Research and Markets (http://www.researchandmarkets.com/research/cn2b2h/global_veterinary) has announced the addition of the "Global Veterinary Medicinal Feed Additives Market Segmented By Products, By Livestock & By Geography - Trends & Forecasts 2014-2019" report to their offering. The Global Veterinary Medicinal feed additives market is estimated at $1.59 billion in 2014. Increasing consumption of meat and dairy products across the globe is expected to propel the market at a CAGR of 4.6 % to reach $2.02 billion by 2019 Epidemics such as bird flu, other diseases such as foot-and mouth-disease, and environmental concerns have led to increased concern over animal health around the globe, due to which, meat producers have increased their focus on feed quality and certification. Typical feed additives include vitamins, trace elements, preservatives, anti-oxidants, etc. Increasing Zoonotic and water borne diseases in animals are a triggering factor for growth in this market. North America and Asia-Pacific are the top two consumers of feed additives in the world, together accounting for more than 60% of the consumption. Asia-Pacific is estimated to be the fastest growing region for medicinal feed additives in terms of revenue. Growth is particularly high in emerging countries such as China, India, and Brazil, because of increasing income levels and rising per capita meat consumption. The restraints of the market are, increasing raw material cost and regulatory structure. This report provides an exhaustive coverage of the market through different categorizations. By type of product - Antibiotics, Vitamins, Antioxidants, Amino Acids, Feed Enzymes, Acidifiers, Prebiotics & Probiotics, Minerals, and Others; By live stock - Swine, Poultry, Cattle, Aquaculture and others Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Global Veterinary Medicinal Feed Additives Market Segmentation 6. Company Profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/cn...veterinary
Companion Animal Health Market 2014-2019 - Opportunities & Forecasts for the $13 Billion Industry
M2 - 19 mins ago
Research and Markets (http://www.researchandmarkets.com/research/wdsnh6/_companion_animal) has announced the addition of the " Companion Animal Health Market By Products, By Diagnostic Technologies, By Animals Type, By Geography-Trends And Forecast (2014-2019)" report to their offering. The global market for companion animal healthcare is valued at $8.5 billion in 2013. Expected to grow at a CAGR of 7.86%, the market is set to reach $13.37 billion by 2019 The companion animal health market is segmented based on type of products i. e Vaccines, Paraciticides, Anti-infectives, Medicinal feed additives, and other pharmaceuticals, based on diagnostics i.e Enzyme Linked Immuno sorbent assay(ELISA), Rapid Immuno Migration( RIM), based on genetics,based on geography market is divided into North America, Asia-Pacific, Europe and Rest of World. Europe accounts for the largest share of the animal vaccines market, followed by North America. The developing regions like Asia-pacific and Africa are expected to form a new revenue pocket in the market. Countries such as India, China, Brazil will be the major contributors in the market. Scope of the Report Products - Vaccines - Paraciticides - Anti-Infectives - Medicinal Feed Additive - Other Pharmaceuticals Diagnostic Technologies Animals Type - Dogs - Cats - Horses Key Topics Covered: 1.Introduction 2. Market Analysis 3. Market Dynamics 4.Market Segmentation 5. Global Companion Animal Diagnostics Market 6. Global Companion Animal Genetics Market 7. Global Companion Market Segmentation, By Geography 8. Competitive landscape 9. Company Profiles - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/wd...ion_animal
Global Veterinary Vaccines Market 2014-2019 - Key Analysis of the $12 Billion Industry
M2 - 56 mins ago
Research and Markets (http://www.researchandmarkets.com/research/rrcznt/global_veterinary) has announced the addition of the "Global Veterinary Vaccines Market Segmented By Veterinary Diseases , By Technology, By Animal Type & By Geography - Trends And Forecast 2014-2019" report to their offering. The global market for veterinary vaccines is estimated to be worth $12.0 billion in 2014 and is expected to grow at a CAGR of 8.8 %, the market is set to reach a value of US$19 billion by 2019 The global veterinary vaccine market is segmented based on type of disease in companion and farm animals - poultry vaccines (Bronchitis, Avian Influenza, Marek's disease, New castle disease), Swine vaccines (Porcine reproductive disease, Swine influenza, Swine Pneumonia). Based on vaccine technology, the market is segmented into toxoid vaccines, recombinant vaccines, Inactivated vaccines and Live attenuated vaccines. Based on geography, the market is divided into North America, Asia-Pacific, Europe and the rest of world. Europe accounts for the largest share of the animal vaccines market, followed by North America. Developing regions like Asia-pacific and Africa are expected to form a new revenue pocket in the market. Countries such as India, China, Brazil will be the major contributors to the market. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Global veterinary vaccine market Segmentation, By Type of Animals,based on diseases 5. Competitive landscape 6. Company profiles 7. Appendix Companies Featured: - Zoetis Animal Healthcare - Merck - Merial (Animal Health Division Of Sanofi) - Elanco - Bayer Healthcare - Novartis Animal Health, Inc. - Virbac - Boehringer Ingelheim For more information visit http://www.researchandmarkets.com/research/rr...veterinary
Asia-Pacific Veterinary Healthcare Market 2014-2020 - Products, Veterinary Diagnostic Technologies, Veterinary Genetics & By Animal Types
M2 - 1 hr 1 min ago
Research and Markets (http://www.researchandmarkets.com/research/qlpr25/asiapacific) has announced the addition of the "Asia-Pacific Veterinary Healthcare Market Segmented By Products, Veterinary Diagnostic Technologies, Veterinary Genetics, By Animal Types - Trends & Forecasts 2014-2019" report to their offering. The Veterinary healthcare market in the Asia-Pacific region is estimated to increase at a CAGR of 8.97% to reach $2.52 billion by 2019 Better standards of living have resulted in an increase in pet ownership and livestock product consumption across the Asia Pacific region. With more pet owners willing to pay for veterinary care, the demand for supplements and other treatment options for companion animals is on the rise. Increasing consumer concern for where and how their food is produced is leading to a tougher scrutiny of feeding and rearing practices of farm animals. All the same, increased competition for cultivated land and scarcity of arable land could affect the animal healthcare market in terms of demand from livestock production. This report provides an exhaustive coverage of the market with multi-level segmentation focusing on animal species (farm animals and companion animals), type of healthcare products (vaccines, paraciticides, anti-infectives, medicinal feed additives, and other pharmaceuticals) and by geography. Regional coverage includes a study of the animal healthcare markets in India, China, Japan. Demand for Veterinary healthcare products and services in Japan is currently the largest of all countries in Asia-Pacific. However, Japan is slated to lose its leader status due heavy regulation requiringrigorous testing - much of it unnecessary. The market for Veterinary pharmaceuticals and biological products in Asia-Pacific has seen scant growth for many years, generally around 1.5%, while global growth has generally been in the 3-4% range. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Animal Types, Based On Products 5. Asia-Pacific Veterinary Diagnostics Market 6. Asia-Pacific Veterinary Genetics Market 7.Animal Species 8. Country Level Analysis 9. Competitive Landscape 10. Company Profiles - Bayer Healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis Animal Healthcare For more information visit http://www.researchandmarkets.com/research/ql...siapacific
Global Veterinary Healthcare Market - Growth, Trends And Forecasts (2014 - 2019)
M2 - 1 hr 1 min ago
Research and Markets (http://www.researchandmarkets.com/research/6g9dn6/global_veterinary) has announced the addition of the "Global Veterinary Healthcare Market - Growth, Trends And Forecasts (2014 - 2019)" report to their offering. The global veterinary health market is valued at $24.80 billion in 2014. Expected to grow at a CAGR of 7.86% to 2019, the demand for animal healthcare products and services globally is set to reach $34.39 billion by 2019 The market is segmented based on type of species (Farm Animals, Companion Animals) and by type of products (Vaccines, Paraciticides, Anti-infectives, Medicinal Feed Additives, and other pharmaceuticals). Based on geography, the market is divided into North America, Asia-Pacific, Europe and the rest of world. Europe accounts for the largest share of the animal vaccines market, followed by North America. Developing regions in Asia-pacific and Africa are expected to form a new revenue pocket in the market. Countries such as India, China, Brazil will be the major contributors to the market. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Market Segmentation- Global Animal Healthcare 5. Competitive landscape 6. Top Players in the Market 7. Appendix Companies Mentioned - Bayer Animal Health - Boehringer Ingelheim - Elanco Animal Health - Merck Ltd. - Merial ( Animal Health division of Sanofi) - Novartis Animal Health - Virbac Animal Health - Zoetis Animal Healthcare For more information visit http://www.researchandmarkets.com/research/6g...veterinary
Global Veterinary Anti-Infectives Market 2014-2020: Segmented By Veterinary Disease Types, By Animal Types & By Geography
M2 - 1 hr 2 mins ago
Research and Markets (http://www.researchandmarkets.com/research/m7q5jd/global_veterinary) has announced the addition of the "Global Veterinary Anti-Infectives Market Segmented By Veterinary Disease Types, By Animal Types & By Geography - Trends & Forecasts 2014-2019" report to their offering. Global market for veterinary anti-infectives is estimated to be worth $4.37 billion in 2014. Expected to grow at a healthy CAGR of 8.5%, the market is set to reach $6.92 billion by 2019 For the past several decades, the veterinary health business units have been able to take advantage of antibiotics that have been sidelined by parent companies and to commercialize, for food animal applications, those products that were considered unsuitable for development as human medicine- owing to market share considerations. The veterinary anti-infectives market is growing at a steady pace to combat the increasing number of infectious diseases in animals.Major constraint for the market is the high raw material cost, which makes anti-infective drugs not easily accessible to a majority of the animal population. However, with continuous innovation and rapid technological advancement, the chances of reducing the cost of anti-infective drugs are high. This report provides an exhaustive coverage of the veterinary anti-infectives market through different categorizations. By type of products - Marbofloaxcine, Florfenicol, Freeze-dried ceftiofur, Beta-lactams, Oxytetracycline and Amminosidin; By species within companion farm animals; By Geography -North America, Asia-Pacific, Europe and Rest of World. Key Topics Covered: 1. Introduction 2.Market Analysis 3.Market Dynamics 4.Global Veterinary Anti-Infective Market Segmentation 5. Competitive landscape 6. Company profiles 7. Appendix Companies Mentioned - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/m7...veterinary
North America Veterinary Healthcare Market - Products, Diagnostic Technologies, Genetics, By Animal Types 2014-2019
M2 - 1 hr 6 mins ago
Research and Markets (http://www.researchandmarkets.com/research/qn5x36/north_america) has announced the addition of the "North America Veterinary Healthcare Market Segmented By Products, Diagnostic Technologies, Genetics, By Animal Types & Geography- Trends & Forecasts-2014-2019" report to their offering. The market for veterinary healthcare products and services in North America is slated to grow at a healthy CAGR to reach $8.6 billion by 2019 from $6.2 billion in 2014 With more pet owners willing to pay for veterinary care, the demand for supplements and other treatment options for companion animals is on the rise. Increasing consumer concern for where and how their food is produced is leading to a tougher scrutiny of feeding and rearing practices of farm animals. All the same, increased competition for cultivated land and scarcity of arable land could affect the animal healthcare market in terms of demand from livestock production. Veterinary healthcare has shifted from providing producers with a set of tools for better livestock productivity to providing safer food sources for the end consumers. Such a shift in priorities, as a result of demand pressures, has played a key role in the rise of demand for this market. Increasing cases of zoonotic and foodborne diseases have prompted tougher regulations and testing procedures, especially in North America, prompting innovation in animal healthcare. This report provides an exhaustive coverage of the market with multi-level segmentation focusing on animal species (farm animals and companion animals), type of healthcare products (vaccines, paraciticides, anti-infectives, medicinal feed additives, and other pharmaceuticals) and by geography. Regional coverage includes a study of the animal healthcare markets in the US, Canada and Mexico. The United States is the largestmarket in this region, owing to ownership trends favoring higher spending on preventative pet healthcareproducts such as parasiticides and supplements with nutritional chemical content. Pfizer, Merck, Sanofi-Aventis, Bayer HealthCare, Virbac, Novartis, Boehringer Ingelheim, Heska Corporation, Bioniche Animal Health Canada, Inc., and Ceva are the key players in the North American animal health care market. Key Topics Covered: 1. Introduction 2 Market Analysis 3. Market Dynamics 4. North America Veterinary healthcare Market Segmentation- Animal Types, based on products 5. North America Veterinary Diagnostics Market 6.North America Veterinary Genetics Market 7. North America Veterinary Healthcare Market Segmentation- By Animal Species 8. North America Veterinary healthcare market- Country level Analysis 9. Competitive landscape 10. Company profiles 11. Appendix Companies Mentioned - Bayer healthcare - Boehringer Ingelheim - Elanco - Merck - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health, Inc. - Virbac - Zoetis animal healthcare For more information visit http://www.researchandmarkets.com/research/qn...th_america
Canada Veterinary Healthcare Market 2014-2019: Animal Types (Farm Animals, Companion Animals, Poultry) & Diagnostics Technologies
M2 - 1 hr 6 mins ago
Research and Markets (http://www.researchandmarkets.com/research/5b25bm/canada_veterinary) has announced the addition of the "Canada Veterinary Healthcare Market- By Animal Types (Farm Animals, Companion Animals, Poultry), By Diagnostics Technologies -Trends And Forecast, 2014 - 2019" report to their offering. The market for vaccines in 2014 is estimated to be US$484 million and is expected to grow at a CAGR of 5.36% between 2011 and 2019, to reach US$628 million by 2019 The market for paraciticides in the region is currently at US$ 113 million - a significant increase from 2013. Increasing focus on food safety and animal health will drive the market for medicinal feed additives to grow at a healthy CAGR of 7%. This report is a study of Canada's veterinary healthcare market, recent trends, current market estimates and forecasts. Veterinary healthcare in Canada has had a significant boost in revenues due to a number of factors. Prominent among them are the escalating occurrence of zoonotic diseases, growing consumer focus on animal health and food safety, and increasing pet ownership. Going forward, the key factor for the growth of Canada's animal health market will be the need to increase production of farm animal products (eggs, milk, beef and other dairy products). Key companies operating in the animal healthcare market in Canada are Zoetis, Merck, Merial, Bayer and Novartis. Growth strategies adopted by these players in the past have differed significantly. While a few like Zoestis and Bayer animal healthcare have focused on horizontal growth by expanding their presence in emerging markets, others like Elanco and Novartis animal healthcare have been content to operate within their established boundaries, going in for vertical growth by product innovation instead. Key Topics Covered: 1. Introduction 2. Key Findings Of The Study 3 Canada Veterinary Healthcare Market - Overview 4. Global Market Analysis 5.Canada's Share In The North America Veterinary Health Care Market. 6. Canada's Veterinary Health Care Market- Market Segmentation By Products 7. Canada's Veterinary Health Care Market- Market Segmentation By Animals 8. The Future Of The Industry-Expert View 9. Key Players' Profile - Global - Bayer Animal Health - Elanco Animal Health - Merck Ltd. - Merial (Animal Health Division Of Sanofi) - Novartis Animal Health - Zoetis Animal Healthcare For more information visit http://www.researchandmarkets.com/research/5b...veterinary
Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 6:15PM CDT
Merck & Co. Inc. (MRK) announced encouraging data from a pivotal phase III fracture outcomes study evaluating the use of odanacatib in postmenopausal women suffering from osteoporosis.
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab
Business Wire - Wed Sep 17, 12:38PM CDT
Merck & Co., Inc. known as MSD outside the United States and Canada, and Sun Pharma through their respective subsidiaries, today announced an exclusive worldwide licensing agreement for Merck's investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment.
Human Microbiome Market - Disease, Application & Products Breakdown - Global Forecast to 2023
M2 - Wed Sep 17, 10:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l4973v/human_microbiome) has announced the addition of the "Human Microbiome Market by Disease, Application & by Product - Global Forecast to 2023" report to their offering. For the purposes of this report, the human microbiome market is segmented by application, disease, product, and geography. The human microbiome market is expected to be valued as $294 million in 2019 and is poised to grow at a CAGR of 22.3% within the forecast period of 2019-2023. The market is driven by growing incidences of unhealthy lifestyle diseases, and increase in occurrence of autoimmune disorders. However, government regulation and lack of detailed research may restrain the growth of this market to an extent. Investing in probiotic and prebiotic products, medical foods, drugs, and devices will prove fruitful for companies in the future. The applications segment is further subdivided into therapeutics and diagnostics. Therapeutics may be the leading segment, owing to growing population and diseases. Currently, the diagnostics segment has fewer products in the pipeline than the therapeutics segment. The disease market is subdivided into the obesity, diabetes, autoimmune disorders, cancer, acute diarrhea, mental disorders and others segments. Of these, obesity and acute diarrhea are expected to be the leading segments; acute diarrhea is expected to show the fastest growth . This growth will driven by the rise in lifestyle diseases, aging population and high adoption rates of approved products. The products segment is subdivided into probiotics, prebiotics, foods, medical foods, other supplements, devices, and drugs. Growth in these segments will be majorly driven due to use of probiotics and prebiotics for maintaining gut flora to avoid lifestyle diseases. The key players in the human microbiome market are Enterome Bioscience (France), Yakult Honsha Co., Ltd. (Japan), E. I. Du Pont de Nemours and company (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome, Inc. ( U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences, Inc. (U.S.), Osel, Inc. (U.S.), and Merck & Co, Inc. (U.S.) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Human Microbiome Market, By Disease 8 Human Microbiome Market, By Application 9 Market, By Product 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles - E. I. Du Pont De Nemours And Company - Enterome Bioscience - Merck & Co., Inc. - Metabiomics Corporation - Microbiome Therapeutics Llc. - Osel Inc. - Second Genome, Inc. - Vedanta Biosciences - Vithera Pharmaceuticals - Yakult Honsha Co., Ltd. For more information visit http://www.researchandmarkets.com/research/l4...microbiome
Sun Pharma licenses Merck psoriasis drug for $80M
AP - Wed Sep 17, 10:10AM CDT
NEW YORK (AP) — Merck is licensing an experimental psoriasis drug to Indian drugmaker Sun Pharmaceuticals, the companies said Wednesday.
Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
Business Wire - Wed Sep 17, 8:31AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Merck's investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to Merck's once-daily DPP-4 inhibitor JANUVIA(R) (sitagliptin) 50 mg, which is the standard starting dose for sitagliptin in Japan. Merck presented these data on omarigliptin, which has been shown to produce sustained DPP-4 inhibition, at an oral session at the 50th European Association for the Study of Diabetes (EASD) Annual Meeting.
Global Hepatitis C Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead, Johnson & Johnson, Merck and Vertex Pharmaceuticals
PR Newswire Europe - Wed Sep 17, 6:26AM CDT
DUBLIN, Sept. 17, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/n8ttk9/global_hepatitis] has announced the addition of the "Global Hepatitis C Market 2014-2018" [http://www.researchandmarkets.com/research/n8ttk9/global_hepatitis] report to their offering.
OncoSec Medical Expands Legal Team, Appoints Sheela Mohan-Peterson as General Counsel and Corporate Secretary
Business Wire - Wed Sep 17, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has appointed Sheela Mohan-Peterson, J.D., M.S. to the position of General Counsel and Corporate Secretary. In this newly created role, she will be responsible for leading the Company's global legal strategy and guiding the continued expansion of its intellectual property portfolio. Ms. Mohan-Peterson will be supported by an experienced internal legal team that includes legal associate and paralegal positions.
Dow Jones (DJIA) Today: Merck (MRK) Higher
at The Street - Tue Sep 16, 1:00PM CDT
The Dow component leading the way higher looks to be Merck (NYSE:MRK), which is sporting a 34-cent gain (+0.6%) bringing the stock to $59.86.
Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis
PR Newswire Europe - Tue Sep 16, 12:53PM CDT
DUBLIN, Sept. 16, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/jq2qvt/global_animal] has announced the addition of the "Global Animal Vaccines Market 2014-2018" [http://www.researchandmarkets.com/research/jq2qvt/global_animal] report to their offering.
